Predictive Factors of Acute Rejection after Early Cyclosporine Withdrawal in Renal Transplant Recipients Who Receive Mycophenolate Mofetil
Authors:
- Marc HazzanMHMarc Hazzan
- Myriam LabaletteMLMyriam Labalette
- Franc[Combining Cedilla]Ois GlowackiFGFranc[Combining Cedilla]Ois Glowacki
- Franc[Combining Cedilla]Ois Provo[Combining Circumflex Accent]TFAFranc[Combining Cedilla]Ois Provo[Combining Circumflex Accent]T
- Franc[Combining Cedilla]Ois-René PruvFPFranc[Combining Cedilla]Ois-René Pruv
- Christian Noe[Combining Diaeresis]LCDChristian Noe[Combining Diaeresis]L
Open Access
- 1 August 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 16 (8) , 2509-2516
Abstract
The aim of this randomized, open-labeled trial was to compare the incidence of acute rejection after an early (3 mo posttransplantation) withdrawal of cyclosporine (CsA) or mycophenolate mofetil (MMF) in renal transplantation. Among 218 eligible recipients, 108 nonsensitized, rejection-free patients who were under a triple drug regimen (CsA-MMF-prednisone) and had received a first kidney from a deceased donor were enrolled. At 3 mo after graft, they were gradually withdrawn from CsA (MMF group, n = 54) or MMF (CsA group, n = 54). A graft biopsy and a pharmacokinetic study of CsA and mycophenolic acid were systematically performed before the randomization. At 1 yr, graft and patient survival rates were 100% in each group. Renal function was improved in the MMF group compared with the CsA group (Cockcroft calculated clearance 64.7 ± 18.7 versus 56.5 ± 18.0 ml/min; P = 0.023). However, the probability of acute rejection was higher in the MMF group (18.5 versus 5.6%; P = 0.045). The 10 patients who developed acute rejection after CsA withdrawal had a significantly higher incidence of borderline changes on the randomization biopsy than the 44 rejection-free patients (five of 10 versus eight of 44; P = 0.034), and they displayed a lower area under the curve of mycophenolic acid (43 ± 9 versus 58 ± 22 mg/h per L; P = 0.045). Multivariate analysis confirmed that borderline changes and area under the curve of mycophenolic acid were significant risk factors of acute rejection after CsA discontinuation. It is concluded that a systematic graft biopsy and a pharmacokinetic study of mycophenolic acid are needed to reduce the risk for acute rejection after CsA withdrawal.Keywords
This publication has 31 references indexed in Scilit:
- Mycophenolic Acid in Diabetic Renal Transplant RecipientsTherapeutic Drug Monitoring, 2004
- Early Adequate Mycophenolic Acid Exposure is Associated with Less Rejection in Kidney TransplantationAmerican Journal of Transplantation, 2004
- Post-transplant renal function in the first year predicts long-term kidney transplant survivalKidney International, 2002
- Withdrawal of Cyclosporine or Prednisone Six Months after Kidney Transplantation in Patients on Triple Drug Therapy: A Randomized, Prospective, Multicenter StudyJournal of the American Society of Nephrology, 2002
- SIROLIMUS ALLOWS EARLY CYCLOSPORINE WITHDRAWAL IN RENAL TRANSPLANTATION RESULTING IN IMPROVED RENAL FUNCTION AND LOWER BLOOD PRESSURE1,2,10Transplantation, 2001
- A RANDOMIZED DOUBLE-BLIND, MULTICENTER PLASMA CONCENTRATION CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ORAL MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION1Transplantation, 1999
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999
- MYCOPHENOLATE MOFETIL IN RENAL TRANSPLANT RECIPIENTS WITH CYCLOSPORINE-ASSOCIATED NEPHROTOXICITYTransplantation, 1998
- Significance of the banff borderline biopsyAmerican Journal of Kidney Diseases, 1996
- EARLY VERSUS LATE ACUTE RENAL ALLOGRAFT REJECTIONTransplantation, 1993